X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Amphista Therapeutics is developing an orally delivered bifunctional non-cereblon / non-VHL-based protein degrader. It is being evaluated in preclinical studies for the treatment of neurodegenerative diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2024
Details:
Under the collaboration, Amphista is responsible for the discovery and development of small molecule protein degraders using Eclipsys™, its next-generation TPD platform and BMS is granted a global exclusive license to the resulting degraders.
Lead Product(s): Targeted Protein Degradation Therapy
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $1,280.0 million Upfront Cash: $30.0 million
Deal Type: Collaboration May 04, 2023
Details:
Under the terms of the agreement, companies will work collaboratively to discover and develop small molecule protein degraders. Bristol Myers Squibb will be granted a global license to the degraders developed and will be responsible for development and commercialization.
Lead Product(s): Targeted Protein Degradation Therapy
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $1,280.0 million Upfront Cash: $30.0 million
Deal Type: Collaboration May 04, 2022
Details:
Amphista and Merck will collaborate to leverage Amphista's proprietary Eclipsys™ TPD platform and generate small molecule protein degraders for an initial three targets in oncology and immunology indications.
Lead Product(s): Targeted Protein Degradation Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: $1,000.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration May 04, 2022
Details:
Amphista believes that Ian Churcher's scientific leadership will be a tremendous addition to the Amphista team as it progresses its TPD pipeline to the clinic.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2020
Details:
This international financing provides Amphista with a firm foundation to underpin a Series B round to progress its oncology pipeline to the clinic.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Advent Life Sciences
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
